Presenter: Garheng Kong, MD, PhD, MBA - Founder and Managing Partner, HealthQuest Capital
Garheng has over two decades of experience in the healthcare field as an investor, physician, scientist, and engineer. His investments and board directorships have resulted in the IPOs of Cempra (CEMP), Alimera (ALIM), Applied Genetic Technology Corp. (AGTC), Proteon (PRTO), Histogenics (HSGX) and TransEnterix (TRXC). He has also had board roles in many M&A transactions that include Calibra Medical (J&J), Cellective (AstraZeneca), Serenex (Pfizer), Athenix (Bayer), NovaMin (GSK), Aldagen (Cytomedix), Salveo Specialty Pharmacy (Catamaran) and SARCode (Shire). Garheng has been asked to Chair the board of seven companies as well.
Garheng currently serves on the boards of Alimera Sciences (ALIM), Castle Biosciences, Cempra (CEMP), First Aid Shot Therapy, Histogenics (HSGX), Strongbridge (SBBP), Trice Medical, Magnolia Medical, and VirMedica. In addition, he holds board seats at Laboratory Corporation of America (LabCorp, NYSE:LH) and Duke University Medical Center Board of Visitors. Garheng’s interests and industry footprint are broad as he also serves on the board of SEBIO, Corporate Chaplains of America, Cure Network Ventures, and advises IDEO Palo Alto and numerous industry groups. He has also served on the Duke Medical Center Institutional Review Board (IRB) and as faculty at the Duke Fuqua School of Business as a senior scholar.
Garheng received two undergraduate degrees, in chemical engineering and biological sciences, from Stanford, which he attended on an athletic scholarship. He then earned his MD, PhD and MBA from Duke University, graduating at the top of his class in each instance. His early career included stints at GlaxoSmithKline, McKinsey and medical device startup TherOx. Garheng has been founder and CEO of two successful biopharma companies (Cellective and Viamet). Prior to HealthQuest, he was a general partner at Intersouth and a general partner at Sofinnova.
4:00-5:00 p.m. | FCIEMAS Schiciano Side A
Reception will begin at 5:00 p.m. in the Schiciano pre-function area